Targeted Therapy Advanced Bootcamp
Log in to see your correct pricing, as SGO members receive a discount.
Content will be added and available to course registrants on October 7, 2024.
Pull, Aim, Squeeze, Treat: Putting the Fire Out on Gynecologic Cancers One Target at a Time
This bootcamp will help prepare Allied Health Professionals to better understand genetic testing, molecular targets of interest, recommend targeted therapies, and manage toxicities related to these newer/novel treatment approaches. As molecular testing is occurring for all gynecologic cancers, being able to utilize these results to the patients’ advantage is critical. The aim is to help those who complete the course to feel more comfortable with the approach and these therapies.
This course is recommended for any allied health member giving chemotherapy, particularly those with at least three years of experience working in gyn onc.
Registration for this course provides access to PDFs of presentation slides and recordings of the live presentations given in September 2024 in conjunction with the SGO 2024 Allied Health Professionals Meeting.
Moderators: Jennifer MacDonald, PharmD, BCOP, and Kathleen Lutz, NP
Speakers:
- Biomarker Testing and Treatment Decisions in Gynecologic Oncology – Terri Earles, DNP, APRN, WHNP-BC, MD Anderson Cancer Center
- Genetics & Testing – Jessica Martineau, MS, CGC, New York University Perlmutter Cancer Center
- Finding the Perfect Match: Integrating Biomarkers, Drug Toxicity, and Patient Characteristics into Targeted Therapy Selection – Stephanie Shuey, PharmD, Duke University
- Case Discussion – Various
Target Audience
NPs, PAs, APPs, Allied Health Professionals
Learning Objectives
1. Understand when to order molecular and genetic testing for patients with gynecologic cancers.
2. Analyze molecular results to review available therapeutic options for women with gynecologic cancers.
3. When given a patient scenario, recommend the best therapy option for a patient and provide patient education for this therapy.
Available Credit
- 2.75 AMA PRA Category 1 Credit™In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this Enduring material for a maximum of 2.75 Enduring AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 2.75 AMA PRA Category 1 Credits™- For Non-physiciansIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PAs may claim a maximum of 2.75 Enduring Category 1 credits for completing this activity. - 2.75 CNE Contact HoursIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 2.75 Enduring ANCC contact hours. - 2.75 Participation